EBD Group is part of the KNect365 of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
ChinaBio Partnering Forum ChinaBio Group EBD Group ChinaBio Partnering Forum
Share/Follow Us
Share this:
Follow this event:

ChinaBio® Partnering Forum Press Releases

May 9, 2016ChinaBio® Partnering Forum 2016 in Suzhou, China is key entry point to global biopharma cross-border partnerships Suzhou, China will host the 8th annual ChinaBio® Partnering Forum 2016 life science partnering event May 18–19. China is the #2 pharmaceutical market and is still growing at 9–15% per year, according to a recent ChinaBio® Group report. As well, over USD 130 billion per year is invested in the China life science industry, with government investment up by ...  more ►

March 14, 2016ChinaBio® Partnering Forum 2016 returning to Suzhou, China's life science hub, May 18–19, 2016 The 8th annual ChinaBio® Partnering Forum 2016 life science partnering event will return to Suzhou, China, May 18–19. Suzhou is an active biopharma hub and the home of international and China pharmaceutical and medical companies, specializing in drug discovery, diagnostics, and medical devices. China is now the world's second largest and fastest growing major pharma market a...  more ►

June 11, 2015Spotlight on Suzhou Business Facts Population Suzhou, in China's Jiangsu Province, has a population of more than 5 million inhabitants and had a growth rate in excess of 6 percent per year between 2000 and 2014, according to 2014 UN data. BioBay innovation cluster BioBay, located in the Dushu Lake Science and Education Innovation District in Suzhou, is an innovative science and technology carrier for developmen...  more ►


partnering360® Blog

May 19, 2016 How drug development is like your diet If you’re like me, you read the dailies. Companies run the gamut from riding high and plump on investment infusion to rock hard abs times when they’re all muscle and no fat, and, possibly back again. With summer coming, it occurred to me that drug development cycles are very much like dieting,... more ►

May 12, 2016 From Zika virus to fast, high quality clinical trials: Puerto Rico’s Consortium for Clinical Investigation (PRCCI) Situated just 1,200 miles from the mainland US, a hotspot of clinical trial activity is being established on a small island paradise. If you haven’t heard of the Puerto Rico Consortium for Clinical Investigation (PRCCI), you should. What this organization is doing in clinical research trials for... more ►

April 29, 2016 Digital Health: Still a brave new world At this year’s BIO-Europe Spring® panel on “The Convergence of Therapeutics and Digital Health,” two panelists from big pharma joined two from Scandinavian digital health companies, agreeing that while the platform for digital health technologies is strong in Europe, much... more ►

April 19, 2016 The characteristics of a “winning” biotech startup QureTech Bio AB, a startup developing first line drugs to combat antibiotic resistance and infectious diseases, won the Start-up Slam: Sweden biotech competition at BIO-Europe Spring® 2016 in Stockholm, Sweden earlier this month. QureTech Bio AB participated in the pitching competition sponsored by... more ►

April 5, 2016 Images of BIO-Europe Spring® 2016 in Stockholm [See image gallery at www.partnering360.com] more ►



partnering360:Insight Latest headlines from partnering360:Insight

May 18, 2016 Italy’s A. Menarini IFR aims to expand into the US and Japan Giammario Piras, corporate licensing director at A. Menarini IFR, explains why and how Italy's largest drug maker plans to expand into the US and Japanese markets. more ►

May 18, 2016 BeyondSpring Pharmaceuticals outlines Plinabulin plans, wants marketing partner BeyondSpring Pharmaceuticals' chief medical officer Ramon Mohanial outlines plans for advancing the group's immuno-oncology pipeline, with ongoing Phase II and III trials of its most promising assets. more ►

May 17, 2016 Accellta CEO says israeli stem cell specialist seeks global partners Itzchak Angel, CEO of Israeli stem cell specialist Accellta, discusses the group's stem cell culturing process and future expansion plans including a planned USD 15 million capital raising exercise and ongoing search for corporate partners. more ►

May 17, 2016 AngioDesign tailoring next-generation ACE inhibitors Mario Ehlers, Chairman of drug discovery group Angio-Design (UK) explains why the design of specific domain-selective ACE inhibitors is expected to produce next-generation drugs that are safer and more effective—and generate blockbuster returns. more ►

May 17, 2016 4SC AG’s CSO outlines epigenetics strategy 4SC AG Chief Science Officer says the German cancer drug developer is conducting a Phase II trial of lead candidate ACE inhibitor resminostat in cutaneous T-cell lymphoma. more ►



Arrow Up

Follow this event:
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD Group
Privacy Policy and Cookies
Terms of Use